Business Context and Reporting Period
This Form 8-K is a Current Report filed by ChromaDex Corporation (CDXC) on September 14, 2021. The filing addresses a significant legal development regarding a patent infringement lawsuit initiated in September 2018 against Elysium Health, Inc. in the United States District Court for the District of Delaware. The dispute concerns U.S. Patents No. 8,383,086 and No. 8,197,807, which grant ChromaDex exclusive rights to the NAD precursor nicotinamide riboside (NR).
Financial Metrics
This filing is a Current Report regarding a specific legal event and does not contain financial statements. Consequently, the document provides no data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the outcome of the pending litigation against Elysium Health, Inc. On September 14, 2021, the court granted a Motion for Summary Judgment in favor of the defendant. As a result, the jury trial originally scheduled to begin on September 27, 2021, has been vacated.
Outlook, Risks, and Management Commentary
Management has stated that the Company plans to appeal the court's decision. The filing includes standard forward-looking statements regarding this appeal, noting that actual results may differ materially due to significant risks and uncertainties. These risks are referenced as being detailed in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company disclaims any obligation to update these forward-looking statements.
Key Facts for Investor Verification
- The court granted a Motion for Summary Judgment against ChromaDex in its patent infringement suit against Elysium Health, Inc.
- The scheduled jury trial for September 27, 2021, has been vacated.
- ChromaDex intends to appeal the summary judgment decision.
- The patents in question (Nos. 8,383,086 and 8,197,807) cover exclusive rights to nicotinamide riboside (NR).
- No financial performance data is included in this specific filing.